Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Seneca Reports Mixed Results from China Stem Cell Trial for Stroke

publication date: Jan 20, 2021

Seneca Biopharma, a Maryland-Suzhou company, reported mixed results from a China trial of its stem cell treatment for ischemic stroke. The Beijing study enrolled 23 patients with stable motor function deficits four months after a stroke. The subjects received an intracerebral injection of stem cells or placebo. Seneca said the active arm showed more improvement than the placebo group, though the results were not statistically significant. Seneca plans to sell rights to NSI-566 after it completes a merger with Leading BioSciences. More details....

Stock Symbol: (NSDQ: SNCA)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.